Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kelly A. Shepard"'
Autor:
Lila R. Collins, Kelly A. Shepard
Publikováno v:
Stem Cells Translational Medicine, Vol 9, Iss 10, Pp 1129-1136 (2020)
Abstract The California Institute for Regenerative Medicine (CIRM) has a mission to accelerate stem cell treatments to patients with unmet medical needs. This perspective describes successful examples of work funded by CIRM's New Cell Lines and Tools
Externí odkaz:
https://doaj.org/article/68bda0156f2f4a519b29c0a72558fbb5
Autor:
Sohel Talib, Kelly A. Shepard
Publikováno v:
Stem Cells Translational Medicine, Vol 9, Iss 4, Pp 420-426 (2020)
Abstract Hematopoietic stem cell transplantation (HSCT) is broadly used for treating and curing hematological cancers and various disorders of the blood and immune system. However, its true therapeutic potential remains vastly constrained by signific
Externí odkaz:
https://doaj.org/article/cbe538ba953f40409049a6332e1439c6
Autor:
Arun Sharma, Rachel A. Clemens, Orquidea Garcia, D. Lansing Taylor, Nicole L. Wagner, Kelly A. Shepard, Anjali Gupta, Siobhan Malany, Alan J. Grodzinsky, Mary Kearns-Jonker, Devin B. Mair, Deok-Ho Kim, Michael S. Roberts, Jeanne F. Loring, Jianying Hu, Lara E. Warren, Sven Eenmaa, Joe Bozada, Eric Paljug, Mark Roth, Donald P. Taylor, Gary Rodrigue, Patrick Cantini, Amelia W. Smith, Marc A. Giulianotti, William R. Wagner
Publikováno v:
Stem Cell Reports
Summary Research in low Earth orbit (LEO) has become more accessible. The 2020 Biomanufacturing in Space Symposium reviewed space-based regenerative medicine research and discussed leveraging LEO to advance biomanufacturing for regenerative medicine
Autor:
Kelly A. Shepard, Sohel Talib
Publikováno v:
Stem Cells Translational Medicine, Vol 9, Iss 4, Pp 420-426 (2020)
Stem Cells Translational Medicine
Stem Cells Translational Medicine
Hematopoietic stem cell transplantation (HSCT) is broadly used for treating and curing hematological cancers and various disorders of the blood and immune system. However, its true therapeutic potential remains vastly constrained by significant scien
Autor:
Kelly A. Shepard
Publikováno v:
Stem Cells Translational Medicine. 4:211-216
Summary In late 2006, the California Institute for Regenerative Medicine (CIRM) launched its first major research initiative to catalyze the nascent field of human embryonic stem cell (hESC) research at a time when federal funding of such studies was
Autor:
Sohel Talib, Kelly A. Shepard
Publikováno v:
Stem Cells Translational Medicine. 3:775-781
On August 29, 2013, the California Institute for Regenerative Medicine (CIRM) convened a small group of investigators in San Francisco, CA, to discuss a longstanding challenge in the stem cell field: the inability to derive fully functional, definiti
Autor:
Carolyn E. Machamer, Cory D. Dunn, Miho Iijima, Kelly A. Shepard, Hiromi Sesaki, Michael P. Yaffe, Robert E. Jensen
Publikováno v:
The Journal of Cell Biology
Mgm1p is a conserved dynamin-related GTPase required for fusion, morphology, inheritance, and the genome maintenance of mitochondria in Saccharomyces cerevisiae. Mgm1p undergoes unconventional processing to produce two functional isoforms by alternat
The mission of the California Institute for Regenerative Medicine (CIRM) is to accelerate stem cell treatments to patients with unmet medical needs. Immune rejection is one hurdle that stem cell therapies must overcome to achieve a durable and effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c19306c17458f07bf80fbd3a2a3e3818
https://europepmc.org/articles/PMC4275016/
https://europepmc.org/articles/PMC4275016/
Autor:
Michael P. Yaffe, Kelly A. Shepard
Publikováno v:
The Journal of Cell Biology
The mdm17 mutation causes temperature-dependent defects in mitochondrial inheritance, mitochondrial morphology, and the maintenance of mitochondrial DNA in the yeast Saccharomyces cerevisiae. Defects in mitochondrial transmission to daughter buds and
Autor:
Geoff rey P Lomax, Kelly A Shepard
Publikováno v:
Stem Cell Research & Therapy
Efforts have emerged internationally to recruit donors with specific disease indications and to derive induced pluripotent cell lines. These disease-specific induced pluripotent stem cell lines have the potential to accelerate translational goals suc